Form 4 for IRON Disc Medicine, Inc.
Accepted 2026-08-07 17:32:31 ET · period of report 2026-08-06 · accession 0001193125-26-340543 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-07 17:32 | 2026-08-06 | IRON | Khara Rahul | CLO | M - OptEx | $14.69 | +5,000 | 57.3K | +10% | +$73.5K |
| DT | 2026-08-07 17:32 | 2026-08-06 | IRON | Khara Rahul | CLO | S - Sale+OE | $80.00 | -5,000 | 52.3K | -9% | -$400.0K |
| DT | 2026-08-07 17:32 | 2026-08-06 | IRON | Khara Rahul | CLO | M - OptEx | $0.00 | -5,000 | 49.8K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-06 | M | A | 5,000 | $14.69 | 57,324 | D | — | — | (F1) The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. (F2) Includes 151 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2026. |
| 2 | Common | Common Stock | 2026-08-06 | S | D | 5,000 | $80.00 | 52,324 | D | — | — | (F1) The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. (F2) Includes 151 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2026. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-08-06 | M | D | 5,000 | $0.00 | 49,804 | D | $14.69 · — to 2032-02-07 | 5,000 Common Stock | (F1) The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. (F3) The shares underlying this option are fully vested and exercisable as of the date hereof. |